Boston Scientific
This article was originally published in The Gray Sheet
Executive Summary
U.S. Department of Justice initiates inquiry relating to events leading up to the firm's Oct. 5 voluntary recall of its NIR ON Ranger with SOX coronary stent delivery system ("The Gray Sheet" Oct. 12, p. 28). The company "is not aware that [DoJ] is doing anything more than gathering information," Boston states, adding "we do not understand [DoJ's] interest in this matter." Separately, Boston is the subject of a recent class action lawsuit in the U.S. District Court for Massachusetts filed by the law firm of Berger & Montague relating to improperly recorded revenues for Japan ("The Gray Sheet" Nov. 9, p. 5)
You may also be interested in...
Abbott Prism Assays, Spectrum Of Product Launches Stalled By QSR Finding
Approval of Abbott Laboratories' Prism hepatitis B core antibody and HIV-1/2 assays likely will be delayed by FDA's finding that Abbott's Lake County, Illinois diagnostic manufacturing facility still does not comply with quality system regulations, the firm said
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.